Skip to main content
OpenTrials
Completed

NCT Number: NCT01768676

Study Evaluating the Effects of Avanafil on Semen Parameters

The purpose of this study is to determine whether avanafil will affect different aspects of sperm production.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Research Facility, Huntsville, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide written informed consent
  • Able to produce semen samples without requiring therapy (PDE5 inhibitors, over-the-counter (OTC) medication, and/or herbal supplements) for erectile dysfunction
  • Be medically healthy (no clinically significant screening results for medical history, electrocardiogram (ECG), laboratory studies, physical examination, etc.) in the opinion of the investigator
  • Be willing and able to comply with all study requirements

Exclusion criteria

  • An International Index of Erectile Function (IIEF) erectile function domain score of less than 17;
  • History of infertility, vasectomy, testicular mass, testicular trauma, testicular abnormality (including size), radiation to the testis, previous pelvic surgery, cryotherapy of the prostate, known sperm defect, or retrograde ejaculation, or cryptorchidism;
  • Resting heart rate <45 or >90 beats per minute at screening (3 rechecks permitted);
  • Screening systolic blood pressure <90 or >140 mmHg and/or diastolic blood pressure <50 or >90 mmHg (3 rechecks permitted);
  • High serum FSH (>18.0 mIU/mL), high serum LH (>18 mIU/mL), or low serum testosterone (< 270 ng/dL, early morning collection) on screening;
  • AST or ALT >2.0 x ULN or other evidence of significant hepatic impairment;
  • Prostate specific antigen (PSA) level ≥4 ng/mL at screening;
  • Individuals who perform rotating shift work during the course of the study.

Treatment and study plan

Avanafil

Drug

100 mg

Other names: TA-1790, Stendra

Placebo

Drug

Primary outcomes

  1. Percentage of Subjects With a Greater Than or Equal to 50% Decrease in Sperm Concentration From Baseline to Week 26

    Time frame: Baseline to Week 26

    Subjects provided 2 semen samples at each visit 2 to 12 days apart. The average value is used as the visit result.

Secondary outcomes

  1. Percentage of Subjects With Greater Than or Equal to 50% Reduction in Sperm Count From Baseline to Week 26

    Time frame: baseline to week 26

  2. Percentage of Subjects With Greater Than or Equal to 50% Reduction in Sperm Motility From Baseline to Week 26

    Time frame: baseline to week 26

    Sperm motility was based upon the WHO grading scale: grade A, B, or C.

  3. Percentage of Subjects With Greater Than or Equal to 50% Reduction in Semen Volume From Baseline to Week 26

    Time frame: baseline to week 26

  4. Percentage of Subjects With Greater Than or Equal to 50% Reduction in Normal Sperm Morphology From Baseline to Week 26

    Time frame: baseline to week 26

Sponsors and collaborators

Lead sponsor

VIVUS LLC

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Jan 15, 2013
Registry last updated
Dec 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.